There are currently 1493 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
NCT05999812
Recruiting
The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 week... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Colorectal Cancer
Register for Updates
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
NCT05762302
Recruiting
This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/27/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Lower Respiratory Tract Infection
Register for Updates
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
01/27/2025
Locations: 139-Texas Retina Associates, Dallas, Texas
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Get With the Guidelines-Stroke Registry
NCT02693223
Recruiting
Get With The Guidelines-Stroke is a program for improving the quality of care for patients hospitalized with stroke by promoting consistent adherence to the latest evidence-based clinical practice guidelines.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
01/27/2025
Locations: Amy Bennett, Dallas, Texas
Conditions: Stroke
Register for Updates
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
NCT04539236
Recruiting
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Myelodysplastic Syndromes
Register for Updates
Get With The Guidelines-Heart Failure Registry
NCT02693509
Recruiting
Get With The Guidelines-Heart Failure is designed to improve the quality of care in patients hospitalized with heart failure. The program aims to help ensure that eligible patients are initiated on guideline recommended therapies and receive appropriate counseling prior to hospital discharge.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
01/27/2025
Locations: Amy Bennett, Dallas, Texas
Conditions: Heart Failure
Register for Updates
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT03692897
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Register for Updates
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
NCT06477692
Recruiting
To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/24/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Head and Neck Cancer
Register for Updates
Post-Operative Thoracolumosacral Orthosis for PJK
NCT06491030
Recruiting
Proximal junctional kyphosis (PJK) is a common post-operative radiographic finding after surgery for adult spinal deformity (ASD) patients. Although the clinical relevance of isolated PJK is unclear, PJK can progress to symptomatic proximal junctional failures which requires a large revision surgery. Currently, post-operative bracing with a thoracolumbosacral orthosis (TLSO) is common practice after spinal deformity surgery, however the efficacy of this in preventing PJK is unknown. This multi-c... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
01/24/2025
Locations: Texas Back Institute, Dallas, Texas
Conditions: Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis
Register for Updates
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774
Recruiting
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/24/2025
Locations: Mary Crowley Cancer Center, Dallas, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty
NCT05493709
Recruiting
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
01/24/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Puberty; Precocious, Central
Register for Updates